Voriconazole CAS#137234-62-9

Voriconazole, with the CAS number 137234-62-9, is a powerful and widely used antifungal agent that has revolutionized the treatment of fungal infections. This broad-spectrum triazole antifungal drug has demonstrated remarkable efficacy in combating a variety of serious fungal pathogens.

Voriconazole exerts its antifungal activity by inhibiting the synthesis of ergosterol, a key component of the fungal cell membrane. By blocking the enzyme lanosterol 14α-demethylase, voriconazole disrupts the normal formation of ergosterol, leading to structural and functional abnormalities in the fungal cell membrane. This results in increased permeability and ultimately leads to the death of the fungal cell. Voriconazole is effective against a wide range of fungal pathogens, including Aspergillus species, Candida species, Fusarium species, and others.

After administration, voriconazole is rapidly absorbed and distributed throughout the body. It has good oral bioavailability, allowing for convenient administration. The drug is metabolized in the liver by the cytochrome P450 enzyme system, mainly by CYP2C19 and CYP3A4. Voriconazole has a relatively long half-life, which allows for less frequent dosing. Its pharmacokinetic properties can be influenced by various factors, such as age, liver function, and drug interactions. Monitoring of serum drug levels may be necessary in certain patient populations to ensure optimal therapeutic efficacy and minimize the risk of toxicity.

Voriconazole is indicated for the treatment of a variety of serious fungal infections. It is particularly useful in the treatment of invasive aspergillosis, which is a life-threatening infection that often occurs in immunocompromised patients. Voriconazole has also shown efficacy in the treatment of candidemia, invasive candidiasis, and other fungal infections. In addition to its use in treating established infections, voriconazole may be used prophylactically in high-risk patients to prevent the development of fungal infections. For example, it may be given to patients undergoing hematopoietic stem cell transplantation or those receiving chemotherapy for cancer.

Voriconazole has had a significant impact on the treatment of fungal infections. Its broad spectrum of activity, good oral bioavailability, and relatively favorable safety profile make it an important tool in the fight against fungal diseases. However, there is still room for improvement in the treatment of fungal infections, and ongoing research is focused on developing new antifungal agents with improved efficacy and safety. In addition, efforts are being made to optimize the use of voriconazole and other antifungal drugs through individualized dosing and combination therapy. As our understanding of fungal pathogenesis and drug resistance continues to evolve, it is likely that new strategies will emerge for the treatment of fungal infections, and voriconazole will continue to play an important role in this field.

Hot Tags: voriconazole cas#137234-62-9, China voriconazole cas#137234-62-9 manufacturers, suppliers